DMAC - NASDAQ

DiaMedica Therapeutics Inc.

DMAC·NASDAQ

$5.84

+1.2%

HealthcareBiotechnology

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$314.68M

EPS-0.7000

P/E Ratio-8.34

Earnings Date08/11/2026

dmac

Net Change in Cash

Last Annual Value

12.62M

3-Year CAGR

744%

5-Year CAGR

29%

10-Year CAGR

120%

Adjust for Inflation

DiaMedica Therapeutics Inc. Competitors Analysis of Net Change in Cash

DMAC · NASDAQ

Company	Net Change in Cash	CAGR 3Y	CAGR 5Y	CAGR 10Y
DiaMedica Therapeutics Inc. NASDAQ:DMAC	12.62M	N/A	N/A	23.2%
I-Mab NASDAQ:IMAB	-242.40M	N/A	N/A	N/A
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	-14.59M	N/A	N/A	N/A
Candel Therapeutics, Inc. NASDAQ:CADL	17.23M	N/A	-18.4%	N/A
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	53.66M	75.3%	N/A	N/A
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	227.19M	N/A	N/A	N/A
Humacyte, Inc. NASDAQ:HUMA	-44.44M	N/A	N/A	N/A
Replimune Group, Inc. NASDAQ:REPL	36.66M	-3.4%	-21.5%	N/A
Galectin Therapeutics Inc. NASDAQ:GALT	2.60M	-28.3%	-27.0%	N/A
Annexon, Inc. NASDAQ:ANNX	112.55M	9.8%	N/A	N/A
Genelux Corporation NASDAQ:GNLX	-3.23M	N/A	N/A	N/A

DiaMedica Therapeutics Inc. Fair Value Envelope

DMAC · NASDAQ

Our analysis suggests that DMAC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.84, this represents a potential HIDDEN relative to our calculated worth for DiaMedica Therapeutics Inc..

HIDDEN

Intrinsic Value

Current Price: $5.84

Related Guides

Blog Categories

Continue your DMAC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.